ResMed CFO’s 1,000‑Share Sale: Market Impact & Insider Trend Analysis
ResMed CFO Brett Sandercock sells 1,000 shares at $257.03, a minimal dip to 0.01%—insider trading reveals steady confidence in ResMed’s sleep‑disorder device business and long‑term strategy.
3 minutes to read